09/28/23 5:00 PMNasdaq : MDNA Medicenna Announces Results of Annual and Special Meeting of ShareholdersMedicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage immuno-oncology company focused on the development of novel Superkines, today announced the voting results from the Company’s annual andRHEA-AIneutral
09/28/23 7:00 AMNasdaq : MDNA conferencesMedicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and ImmunotherapyMedicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, announced that the Company will present preclinical results featuring itsRHEA-AIneutral
09/06/23 7:00 AMNasdaq : MDNA conferencesMedicenna to Participate at The H.C. Wainwright 25th Annual Global Investment ConferenceMedicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, announced that Dr. Fahar Merchant, President and CEO is scheduled toRHEA-AIneutral
08/28/23 7:00 AMNasdaq : MDNA managementMedicenna Announces the Appointment of Jeff Caravella as Chief Financial OfficerJeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella’s appointment demonstrates Medicenna’s continuing commitment to establish its presence in Boston, the leadingRHEA-AIneutral
08/14/23 7:00 AMNasdaq : MDNA managementMedicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters ManagementCompany to grow business development, financing and clinical leadership in Boston by accessing top-biotech talent. Brent Meadows, MBA, joins as Chief Business Officer (CBO), bringing over 25 years of large pharma and biotech experience and a track record of multiple high-value transactions inRHEA-AIpositive
08/09/23 7:30 AMNasdaq : MDNA clinical trialMedicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study- Durable anti-cancer activity was observed during monotherapy dose escalation without dose-limiting toxicities - Late-stage pancreatic cancer patient achieved 80% tumor shrinkage with complete regression observed in two of three metastatic lesions in the liver in response to single-agent MDNA11 -RHEA-AIneutral
08/08/23 7:00 AMNasdaq : MDNA managementMedicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today theRHEA-AIneutral
08/04/23 7:00 AMNasdaq : MDNA clinical trialMedicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today that it will host a conference call and live webcast on August 9, 2023 at 8:30AM ET to provide aRHEA-AIneutral
08/01/23 9:30 AMNasdaq : MDNA Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in OncologyMedicenna Therapeutics Corp. has been granted U.S. Patent No. 11,680,090 titled “Interleukin-2 Fusion Proteins and Uses Thereof.” The patent covers a method for enhancing immune cell survival and proliferation or inhibiting cell death and therefore improving fitness of cancer fighting immune cells.RHEA-AIpositive
07/28/23 7:00 AMNasdaq : MDNA earningsMedicenna Reports First Quarter Fiscal 2024 Financial Results and Operational HighlightsSafety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1 portion of the ABILITY Study as there were no protocol defined dose-limiting toxicities MDNA11 clinical update scheduled for August 9; conference call to discuss data from cohorts five and six, recommended dose forRHEA-AIneutral